Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings

PURPOSE: Amikacin liposome inhalation suspension (ALIS), which efficiently allows amikacin to reach the pulmonary periphery for effect while minimising systemic adverse effects, was recently approved for treating Mycobacterium avium complex (MAC) infections. The international Phase 3 open-label clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Atsuho, Namkoong, Ho, Yagi, Kazuma, Asakura, Takanori, Hosoya, Makoto, Tanaka, Hiromu, Lee, Ho, Ogawa, Takunori, Kusumoto, Tatsuya, Azekawa, Shuhei, Nakagawara, Kensuke, Kamata, Hirofumi, Ishii, Makoto, Fukunaga, Koichi, Ozawa, Hiroyuki, Hasegawa, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342928/
https://www.ncbi.nlm.nih.gov/pubmed/35924016
http://dx.doi.org/10.2147/IDR.S373783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342928/
https://www.ncbi.nlm.nih.gov/pubmed/35924016
http://dx.doi.org/10.2147/IDR.S373783

Ejemplares similares